Every material Form 8-K Senti Biosciences Holdings, Inc. has filed with the SEC since October 13, 2026, read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). Newest first; each brief links to its own page and to the filing on SEC.gov.
Edward Mathers resigned from the Senti Biosciences board and all its committees, effective immediately, on October 27, 2026. The Board also set October 30, 2026 as the record date for the previously announced distribution of contingent value rights (CVRs) tied to the merger that closed October 21, 2026.
Edward Mathers resigned from the Board and all committees, effective immediately on October 27, 2026.
Board fixed close of business on October 30, 2026 as the record date for the CVR distribution.
CVRs relate to the merger agreement dated July 14, 2026, which closed October 21, 2026.
On October 21, 2026, Senti Biosciences completed a merger in which it divested its entire ownership interest in its Midco and Opco subsidiaries to Parent, which acquired substantially all of the company's existing business and pipeline. Shareholders receive contingent value rights that may pay up to $60.0 million on SENTI-202 milestones, but the filing says these payments are highly speculative and may never be paid, and that the company may not be able to maintain operations as early as the fourth quarter of 2026.
Merger closed October 21, 2026; the company received no cash at closing and divested Midco and Opco.
CVRs may pay up to $60.0 million in total: $10.0 million on BLA filing or acceptance, $20.0 million on FDA approval, and $30.0 million on cumulative net sales above $200.0 million.
The company sold 7,309,941 shares at $0.342 per share to CPIF II-7 Limited for about $2.5 million.
The company estimates a loss on disposal of $6.652 million and says it may not be able to maintain operations as early as Q4 2026.
Senti Biosciences adjourned its virtual 2026 Annual Meeting of Stockholders on October 8, 2026 without conducting any business, though a quorum was present. The company said it needs more time to solicit stockholder votes in favor of the Merger Agreement Proposal, and the meeting will reconvene on October 15, 2026. For shareholders, the vote on the proposed merger remains open, and no changes were made to the proposals.
Annual Meeting convened October 8, 2026 and adjourned without conducting business; a quorum was present
Meeting reconvenes Thursday, October 15, 2026 at 8:00 a.m. Pacific time, virtually
Company is seeking more votes in favor of the Merger Agreement Proposal; polls remain open and no proposals changed
Record date remains September 23, 2026; stockholders who already voted need not act
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Only material 8-Ks get a brief: results, deals, executive changes, restructuring, impairments, delisting notices, restatements, cybersecurity incidents and other disclosed events. Routine filings (vote results, exhibits only) are skipped. Every Senti Biosciences Holdings, Inc. filing is on SEC EDGAR ↗. 8-K briefs of other companies →